Markovic, M.; Ben-Shabat, S.; Nagendra Manda, J.; Abramov-Harpaz, K.; Regev, C.; Miller, Y.; Aponick, A.; Zimmermann, E.M.; Dahan, A.
PLA2-Triggered Activation of Cyclosporine-Phospholipid Prodrug as a Drug Targeting Approach in Inflammatory Bowel Disease Therapy. Pharmaceutics 2022, 14, 675.
https://doi.org/10.3390/pharmaceutics14030675
AMA Style
Markovic M, Ben-Shabat S, Nagendra Manda J, Abramov-Harpaz K, Regev C, Miller Y, Aponick A, Zimmermann EM, Dahan A.
PLA2-Triggered Activation of Cyclosporine-Phospholipid Prodrug as a Drug Targeting Approach in Inflammatory Bowel Disease Therapy. Pharmaceutics. 2022; 14(3):675.
https://doi.org/10.3390/pharmaceutics14030675
Chicago/Turabian Style
Markovic, Milica, Shimon Ben-Shabat, Jagadeesh Nagendra Manda, Karina Abramov-Harpaz, Clil Regev, Yifat Miller, Aaron Aponick, Ellen M. Zimmermann, and Arik Dahan.
2022. "PLA2-Triggered Activation of Cyclosporine-Phospholipid Prodrug as a Drug Targeting Approach in Inflammatory Bowel Disease Therapy" Pharmaceutics 14, no. 3: 675.
https://doi.org/10.3390/pharmaceutics14030675
APA Style
Markovic, M., Ben-Shabat, S., Nagendra Manda, J., Abramov-Harpaz, K., Regev, C., Miller, Y., Aponick, A., Zimmermann, E. M., & Dahan, A.
(2022). PLA2-Triggered Activation of Cyclosporine-Phospholipid Prodrug as a Drug Targeting Approach in Inflammatory Bowel Disease Therapy. Pharmaceutics, 14(3), 675.
https://doi.org/10.3390/pharmaceutics14030675
